Stocks
Amgen Stock Jumps 2% on Sjogren's Disease Therapy Breakthrough
Amgen's stock rose 2% to $393.64 on September 7, 2026, following news that its Phase 3 study of an investigational therapy for moderate-to-severe Sjogren's disease activity reached its primary endpoint.
The company's shares have been trading near a market value of $212.56 billion and trailing revenue of $38.09 billion.
A majority of analysts, 54 out of 136, rate Amgen stock as a 'buy', with HSBC setting a price target of $425 with a hold rating.